Publication | Closed Access

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age☆

VaccinologyVaccine SafetyVaccinationVaccine DevelopmentHealthy Adults 50–64ImmunologyImmunodominanceInfluenza VaccineFlu VaccinationMedicineVaccine ResearchInfluenza Vaccines